拉米夫定联合中草药治疗慢性乙型肝炎疗效观察

doi:10.3969/j.issn.1672-5069.2016.03.022

Abstract

Aoduntuoya. Clinical study of combination of Chinese herbal medicine and lamivudine in treating patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 343-344.

[1] Fasano M，Lampertico P，Marzano A，et al. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol，2012，56（6）:1254-1258.
[2] Soriano V，Mcmahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antivir Res，2013，100（2）:435-438.
[3] 周文兴，吕国良，刘馨，等. 核苷类药物在乙型肝炎后肝硬化治疗中的疗效分析. 中国生化药物杂志，2012，33（2）:170-172.
[4] Block TM，Gish R，Guo H，et al. Chronic hepatitis B:What should be the goal for new therapies Antivir Res，2013，98（1）:27-34.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）：81-89.
[6] 刘小芳，马建，李永华，等. 慢性乙型肝炎中医辨证分型与肝功能指标关系思考. 现代中西医结合杂志，2012，21（9）:1016-1018.
[7] Kanda T，Shinozaki M，Kamezaki H，et al. Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B. Int J Med Sci，2012，9（1）:27-32.
[8] 褚卫明，那丽颖，黄利华，等. 拉米夫定联合阿德福韦酯治疗慢性乙型肝炎的临床研究. 实用医学杂志，2012，28（22）:3815-3817.
[9] 严颖，麦丽，郑玉宝，等. 慢性乙型肝炎患者血清HBV DNA载量与肝组织病理改变的分析. 中山大学学报（医学科学版），2012，33（4）:486-489.
[10] 王恩成，唐琳，王健，等. 慢性乙型肝炎中医证候聚类分析研究.中国中西医结合杂志，2014，34（1）:39-42.
[11] 袁晓鸣.甘露消毒丹及其临床应用.河南中医，2012，32（1）:95-96.
[12] Wang YC，Zhang L，Hao LI，et al. Clinical efficacy of telbivudine and lamivudine in HBeAg positive chronic hepatitis B patients. Chin J Clin Pharmacol，2014，30（6）:487-489.
[13] Ismail AM，Samuel P，Ramachandran J，et al. Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent:Antiviral resistance mutations and predictive factors of treatment response. Mol Diagn Ther，2014，18（1）:63-71.
[14] Hsu YC，Mo LR，Chang CY，et al. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation. Antivir Ther，2012，17（4）:605-612.
[15] Suzuki F，Hosaka T，Suzuki Y，et al. Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. J Gastroenterol Hepatol， 2014， 49（6）:1094-1104.

Clinical study of combination of Chinese herbal medicine and lamivudine in treating patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[7]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[8]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[9]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[10]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[11]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[12]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[13]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[14]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[15]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.